Age: 20.0
Sex: M
Vaccine: COVID19, COVID19, UNK
Symptoms: Exfoliative rash, Interchange of vaccine products, Psoriasis, Rash pustular
Clinical narrative: Interchange of vaccine products; Rash scaly/scaly rash in groin region; Psoriasis/POSSIBLE PSORIASIS; Pustular rash; This spontaneous case was reported by a consumer and describes the occurrence of EXFOLIATIVE RASH (Rash scaly/scaly rash in groin region), PSORIASIS (Psoriasis/POSSIBLE PSORIASIS), RASH PUSTULAR (Pustular rash) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for an unknown indication and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form, ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 01-Jun-2022, the patient experienced EXFOLIATIVE RASH (Rash scaly/scaly rash in groin region), PSORIASIS (Psoriasis/POSSIBLE PSORIASIS) and RASH PUSTULAR (Pustular rash). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, EXFOLIATIVE RASH (Rash scaly/scaly rash in groin region), PSORIASIS (Psoriasis/POSSIBLE PSORIASIS) and RASH PUSTULAR (Pustular rash) had not resolved and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved.            No concomitant medication was reported. No treatment medication was provided. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   Company comment- This is a spontaneous case of interchange of vaccine products (received a dose of TOZINAMERAN vaccine, reported as co-suspect) concerning a 20-year-old male patient treated with Adalimumab (reported as co-suspect) for an unknown indication, who experienced the unexpected non-serious  exfoliative rash.  A dose of mRNA-1273 vaccine, given as a booster dose of COVID vaccine schedule, was administered. Vaccination date was not provided; hence, latency cannot be assessed. It was reported patient had scaly rash in groin region, possible psoriasis and pustular type rash which looks like pimple. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This is a spontaneous case of interchange of vaccine products (received a dose of TOZINAMERAN vaccine, reported as co-suspect) concerning a 20-year-old male patient treated with Adalimumab (reported as co-suspect) for an unknown indication, who experienced the unexpected non-serious  exfoliative rash.  A dose of mRNA-1273 vaccine, given as a booster dose of COVID vaccine schedule, was administered. Vaccination date was not provided; hence, latency cannot be assessed. It was reported patient had scaly rash in groin region, possible psoriasis and pustular type rash which looks like pimple. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.